Rhythm Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RYTM research report →
Companywww.rhythmtx.com
Rhythm Pharmaceuticals, Inc. , a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
- CEO
- David Meeker
- IPO
- 2017
- Employees
- 283
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $6.13B
- P/E
- -30.00
- P/S
- 28.23
- P/B
- 49.47
- EV/EBITDA
- -34.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.41%
- Op Margin
- -90.89%
- Net Margin
- -93.33%
- ROE
- -203.25%
- ROIC
- -56.40%
Growth & Income
- Revenue
- $189.76M · 45.83%
- Net Income
- $-196,539,000 · 24.58%
- EPS
- $-3.11 · 28.34%
- Op Income
- $-192,016,000
- FCF YoY
- -2.41%
Performance & Tape
- 52W High
- $122.20
- 52W Low
- $58.72
- 50D MA
- $87.18
- 200D MA
- $98.66
- Beta
- 1.94
- Avg Volume
- 879.78K
Get TickerSpark's AI analysis on RYTM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | German Christopher Paul | other | 1,406 |
| May 15, 26 | German Christopher Paul | other | 1,687 |
| May 15, 26 | German Christopher Paul | other | 1,349 |
| May 15, 26 | German Christopher Paul | other | 1,349 |
| May 15, 26 | German Christopher Paul | other | 1,406 |
| May 15, 26 | German Christopher Paul | other | 1,687 |
| May 15, 26 | German Christopher Paul | sell | 4,643 |
| Apr 1, 26 | Mazabraud Yann | other | 12,875 |
| Apr 1, 26 | Mazabraud Yann | other | 10,375 |
| Apr 1, 26 | Mazabraud Yann | other | 2,500 |
Our RYTM Coverage
We haven't published any research on RYTM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RYTM Report →